← Back to Screener
Omeros Corporation (OMER)
Price$10.72
Value ScoreC
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)18.21%
Price vs S&P 500 (4W)-31.67%
VGM Score55.68
Market Capitalization$799.02M
All Metrics
Book Value / Share (Quarterly)$0.33
P/TBV (Annual)3.46x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.32
Price vs S&P 500 (YTD)-46.67%
Gross Margin (TTM)94.07%
Net Profit Margin (TTM)566.66%
EPS (TTM)$0.94
10-Day Avg Trading Volume1.96M
EPS Excl Extra (TTM)$0.94
EPS (Annual)$-2.71
ROI (Annual)8.98%
Gross Margin (Annual)98.78%
Net Profit Margin (5Y Avg)-185.94%
Cash / Share (Quarterly)$1.88
P/E Basic Excl Extra (TTM)9.27x
ROA (Last FY)-56.66%
EBITD / Share (TTM)$-1.26
ROE (5Y Avg)111.99%
Operating Margin (TTM)-176.09%
Cash Flow / Share (Annual)$-1.62
P/B Ratio38.96x
P/B Ratio (Quarterly)16.66x
Net Income / Employee (Annual)$-897,100
EV / Revenue (TTM)110.76x
Net Interest Coverage (TTM)-4.67x
ROA (TTM)34.53%
EV / EBITDA (TTM)7.42x
EPS Incl Extra (Annual)$-2.71
Current Ratio (Annual)2.76x
Quick Ratio (Quarterly)2.91x
3-Month Avg Trading Volume1.23M
52-Week Price Return232.53%
P/E Incl Extra (TTM)9.27x
Revenue / Employee (TTM)$56,500
Tangible BV / Share (Quarterly)$2.03
P/S Ratio (Annual)10.83x
Asset Turnover (Annual)0.41x
52-Week High$17.65
Operating Margin (5Y Avg)-171.04%
EPS Excl Extra (Annual)$-2.71
CapEx CAGR (5Y)-25.33%
26-Week Price Return34.14%
Quick Ratio (Annual)2.67x
13-Week Price Return-4.42%
Total Debt / Equity (Annual)5.16x
Current Ratio (Quarterly)3.03x
Enterprise Value$1.10B
Asset Turnover (TTM)0.03x
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.72x
Pretax Margin (Annual)-203.39%
Cash / Share (Annual)$2.40
3-Month Return Std Dev62.16%
Gross Margin (5Y Avg)98.25%
Net Income / Employee (TTM)$492,400
ROE (Last FY)55.34%
Net Interest Coverage (Annual)1.30x
EPS Basic Excl Extra (Annual)$-2.71
P/FCF (TTM)1.38x
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)21.55x
EPS Incl Extra (TTM)$0.94
Receivables Turnover (Annual)0.00x
ROI (TTM)11.65%
P/S Ratio (TTM)80.77x
Pretax Margin (5Y Avg)-197.82%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.03
Forward P/E58.47x
Price vs S&P 500 (52W)204.32%
P/E Ratio (TTM)9.27x
Year-to-Date Return-35.74%
5-Day Price Return-3.66%
EPS Normalized (Annual)$-2.71
ROA (5Y Avg)-21.95%
Net Profit Margin (Annual)-187.13%
Month-to-Date Return-24.38%
Cash Flow / Share (TTM)$-2.88
EBITD / Share (Annual)$-2.90
Operating Margin (Annual)-168.02%
LT Debt / Equity (Annual)4.04x
ROI (5Y Avg)-36.17%
P/E Excl Extra (TTM)9.27x
LT Debt / Equity (Quarterly)16.70x
EPS Basic Excl Extra (TTM)$0.94
P/TBV (Quarterly)3.46x
P/B Ratio (Annual)1.65x
Inventory Turnover (TTM)0.75x
Pretax Margin (TTM)518.61%
Book Value / Share (Annual)$1.36
Price vs S&P 500 (13W)-14.16%
Beta2.56x
P/FCF (Annual)10.75x
Revenue / Share (TTM)$0.11
ROE (TTM)107.50%
52-Week Low$2.95
vGradeC
mGradeB
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.24est. -0.41
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
OMEROmeros Corporation | C | — | B | $10.72 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Omeros is a clinical-stage biopharmaceutical company developing targeted therapies for complement-mediated diseases and immunologic disorders. The company's lead candidate, narsoplimab, is a monoclonal antibody in clinical trials for rare immune-related conditions including thrombotic microangiopathy following stem cell transplantation and immunoglobulin nephropathy. Omeros also has programs targeting cancer and additional large-market immunologic indications.